Top Markets
#1 Status Status +20.04%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.47%
#3 Ontology Gas Ontology Gas +12.46%
#4 GoPlus Security GoPlus Security +12.16%
#5 DMT-NAT DMT-NAT +9.70%
#6 Fake World Assets Fake World Assets +8.34%
#7 Provenance Blockchain Provenance Blockchain +6.75%
#8 Bedrock Bedrock +6.48%
#9 Janction Janction +6.24%
#10 Ontology Ontology +5.54%
Coin of the day
Status Status
設定
言語
日本
通貨
USD
テーマ
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
株式のランク #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
株価
$0.1502
最終同期: 2024-11-04
時価総額
$6.43M
変化（1日）
-5.45%
変化（1年）
0.00%
国
US
取引 Renalytix Plc (RNLX)

カテゴリー

Healthcare
Renalytix Plc（RNLX）の営業利益率
August 2026 時点の営業利益率 TTM: -1,293.49%
Renalytix Plc の最新の財務報告と株価によると、現在の営業利益率（TTM）は -1,293.49% です。2023 年末時点では -1,244.64% でした。
Renalytix Plc の営業利益率の履歴（2018 から 2026）
各年末の営業利益率
年 営業利益率 変化
2026 (TTM) -1,293.49% 0.00%
2024 -1,293.49% 3.92%
2023 -1,244.64% -35.57%
2022 -1,931.72% -11.68%
2021 -2,187.19% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
同業他社の営業利益率
企業 営業利益率 営業利益率の差 国
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
12.70% -100.01%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
74.17% -100.06%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
3.33% -100.00%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
-19.76% -99.98%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
0.00% -
US
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。